ANRO

– Independent, peer-reviewed, placebo-controlled trial conducted by Lund University showed pramipexole significantly reduced anhedonia (primary endpoint, Hedges' g=0.62, p=0.006) – – Benefit extended to independent anhedonia and apathy measures (DARS, AES-S) and was sustained through six months of open-label treatment – – Findings reinforce the dopaminergic mechanism underlying ALTO-207; potentially pivotal Phase 2b trial in treatment-resistant depression is ongoing with data expected in 2H 2027 – Alto Neuroscience, Inc. ("Alto") (NYSE:ANRO) today highlighted the publication in Nature Medicine of PRIME-PRAXOL, an independent, randomized, double-blind, placebo-controlled trial of the d

4 - Alto Neuroscience, Inc. (0001999480) (Issuer)

3 - Alto Neuroscience, Inc. (0001999480) (Issuer)

8-K - Alto Neuroscience, Inc. (0001999480) (Filer)

Miller brings deep neuropsychiatry drug development and value creation experience, having led R&D at Karuna Therapeutics through its $14 billion acquisition by Bristol Myers Squibb Alto Neuroscience, Inc. ("Alto") (NYSE:ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced the appointment of Andrew Miller, Ph.D. to its Board of Directors, effective May 27, 2026. "We are thrilled to welcome Andrew to Alto's Board at a transformative time for the Company," said Amit Etkin, M.D., Ph.D., Founder and Chief Executive Officer of Alto Neuroscience. "Few leaders in our industry have done more to a

Wolfe Research initiated coverage of Alto Neuroscience with a rating of Outperform

4 - Alto Neuroscience, Inc. (0001999480) (Issuer)

SCHEDULE 13G/A - Alto Neuroscience, Inc. (0001999480) (Subject)

SCHEDULE 13G/A - Alto Neuroscience, Inc. (0001999480) (Subject)

SCHEDULE 13G/A - Alto Neuroscience, Inc. (0001999480) (Subject)

Alto Neuroscience, Inc. (NYSE:ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today congratulates founder and CEO Amit Etkin, M.D., Ph.D. on receiving the Transformational Research Award from the VP&S Alumni Association at Columbia University Vagelos College of Physicians and Surgeons. This award honors VP&S alumni who are making transformational contributions to biomedical research within 25 years of graduation. "Having led global neuroscience R&D efforts for many years, I recognize that true transformation requires moving beyond the 'one-size-fits-all' model," said Husseini Manji, M.D., member of t

4 - Alto Neuroscience, Inc. (0001999480) (Issuer)

4 - Alto Neuroscience, Inc. (0001999480) (Issuer)

4 - Alto Neuroscience, Inc. (0001999480) (Issuer)

4 - Alto Neuroscience, Inc. (0001999480) (Issuer)

4 - Alto Neuroscience, Inc. (0001999480) (Issuer)

8-K - Alto Neuroscience, Inc. (0001999480) (Filer)

10-Q - Alto Neuroscience, Inc. (0001999480) (Filer)

8-K - Alto Neuroscience, Inc. (0001999480) (Filer)

– Phase 2b clinical trial of ALTO-207 in treatment-resistant depression (TRD) initiated – – New ALTO-101 analyses support significant effects on EEG markers of general cognition as well as a test of attention – – Closed $120 million PIPE in March 2026; cash balance of approximately $264 million expected to fund planned operations through 2029, including a potential NDA submission for ALTO-207 – Alto Neuroscience, Inc. ("Alto") (NYSE:ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today reported financial results for the quarter ended March 31, 2026, and highlighted recent progress across its pipe

Alto Neuroscience, Inc. ("Alto") (NYSE:ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that members of the Company's management team will participate in the following upcoming investor conferences: Bank of America Securities Healthcare Conference, May 12-14, 2026 Format: Company presentation and one-on-one meetings Presentation Date & Time: May 13, 2026, 5:15 pm PDT Location: Las Vegas, NV Jefferies Global Healthcare Conference, June 2-4, 2026 Format: Fireside chat and one-on-one investor meetings Presentation Date & Time: June 3, 2026, 9:20 am EDT Location: Ne

BofA Securities initiated coverage of Alto Neuroscience with a rating of Buy and set a new price target of $35.00

— Randomized, placebo-controlled, Phase 2a trial demonstrated robust, statistically significant antidepressant effects of ALTO-207 and favorable tolerability; supporting development of ALTO-207 in ~7 million patient treatment-resistant depression market — — Phase 2b Ongoing with topline data expected in 2H 2027 — Alto Neuroscience, Inc. (NYSE:ANRO), a clinical-stage biopharmaceutical company focused on precision medicines for neuropsychiatric disorders, today announced the presentation of data from a randomized, single-blind, placebo-controlled Phase 2a trial of ALTO-207 (formerly CTC-501) in patients with Major Depressive Disorder (MDD). The data were presented in a poster session at t

— Phase 2b closely resembles PAX-D study design, which demonstrated an effect size for pramipexole more than two times larger than approved TRD therapies — — Trial design and MADRS primary endpoint aligned with FDA standards in depression, potentially supporting a single Phase 3 registrational pathway — — Prior Phase 2a demonstrated robust antidepressant effects of ALTO-207 and favorable tolerability — — Topline data expected in 2H 2027 — Alto Neuroscience, Inc. (NYSE:ANRO), a clinical-stage biopharmaceutical company focused on precision medicines for neuropsychiatric disorders, today announced the initiation of a Phase 2b randomized, placebo-controlled trial of ALTO-207 in treatmen

EFFECT - Alto Neuroscience, Inc. (0001999480) (Filer)